Santen Pharmaceuticals Acquires Asia Rights for Ophthalmic Pharmaceutical From MacuSight

Represented Santen Pharmaceutical Co. Ltd. in its acquisition of Asia Rights to Sirolimus for Ophthalmology from MacuSight for $50 million upfront, plus milestones and royalties.

Drug Manufacturing

Related Practices

Related Industries & Initiatives

Related Attorneys

Lawrence B. Cohn

Of Counsel

Corporate & Securities

Related Experience

Santen Pharmaceuticals Enters Into Worldwide License and Collaboration With Merck

Santen Pharmaceuticals Announces Strategic Investment in Regenerative Patch Technologies LLC

Santen Pharmaceutical Co., Ltd. Purchases Rights to Ophthalmic Drugs From Merck

Santen Enters into Collaboration and Distribution Agreement with Glaukos